TreeWAS
Search
Variant clusters
Hospitalization Episode Statistics (HES)
Genetic variants: 36,212
Diagnostic terms: × 19,155
Association results: = 693,640,860
Self-Reported Statistics (SRS)
Genetic variants: 28,458
Diagnostic terms: × 474
Association results: = 13,489,092
About
Frequently Asked Questions
Citation
Download association data
for this variant in csv format
Share this page

Variant-specific associations

rs9266490
log Bayes Factor = 52.0428
Chromosome 6   position 31,340,158  (GRCh37) Explore rs9266490 on Ensembl!

Hospitalization Episode Statistics (HES)

Self-Reported Statistics (SRS)

Hierarchical visualisation How to interpret this figure?
Associations at terminal nodes are shown if p(effect) ≥
Click here to show this figure without filtering.
Click on a node to zoom (except terminal nodes).
Download this figure in format
Results table
Term Risk
posterior probability
 No effect
posterior probability
 Protective
posterior probability
  
E03.9 Hypothyroidism, unspecified
0.000 0.000 1.000
K90.0 Coeliac disease
0.000 0.000 1.000
L40.9 Psoriasis, unspecified
1.000 0.000 0.000
E10 Insulin-dependent diabetes mellitus
1.000 0.000 0.000
L40 Psoriasis
1.000 0.000 0.000
E10-E14 Diabetes mellitus
1.000 0.000 0.000
L40.5 Arthropathic psoriasis
0.999 0.001 0.000
E11 Non-insulin-dependent diabetes mellitus
0.998 0.002 0.000
E10.9 Without complications
0.996 0.004 0.000
E11.4 With neurological complications
0.983 0.017 0.000
E10.4 With neurological complications
0.974 0.026 0.000
E10.3 With ophthalmic complications
0.953 0.047 0.000
E11.3 With ophthalmic complications
0.940 0.060 0.000
M45.X9 Ankylosing spondylitis (Site unspecified)
0.000 0.068 0.932
Chapter IV Endocrine, nutritional and metabolic diseases
0.925 0.075 0.000
L40.0 Psoriasis vulgaris
0.912 0.088 0.000
E11.1 With ketoacidosis
0.908 0.092 0.000
E11.0 With coma
0.893 0.107 0.000
E14 Unspecified diabetes mellitus
0.881 0.119 0.000
M45 Ankylosing spondylitis
0.000 0.120 0.880
E15-E16 Other disorders of glucose regulation and pancreatic internal secretion
0.877 0.123 0.000
E11.2 With renal complications
0.875 0.125 0.000
E03 Other hypothyroidism
0.012 0.132 0.855
E10.0 With coma
0.860 0.140 0.000
M45.X0 Ankylosing spondylitis (Multiple sites in spine)
0.000 0.145 0.855
E16 Other disorders of pancreatic internal secretion
0.842 0.158 0.000
T36-T50 Poisoning by drugs, medicaments and biological substances
0.832 0.168 0.000
T43 Poisoning by psychotropic drugs, not elsewhere classified
0.830 0.170 0.000
E10.1 With ketoacidosis
0.829 0.171 0.000
E00-E07 Disorders of thyroid gland
0.024 0.184 0.792
T43.2 Other and unspecified antidepressants
0.815 0.185 0.000
E16.2 Hypoglycaemia, unspecified
0.815 0.185 0.000
E10.8 With unspecified complications
0.811 0.189 0.000
T39 Poisoning by nonopioid analgesics, antipyretics and antirheumatics
0.811 0.189 0.000
E14.9 Without complications
0.808 0.192 0.000
T39.1 4-Aminophenol derivatives
0.806 0.194 0.000
E05 Thyrotoxicosis [hyperthyroidism]
0.010 0.211 0.779
E10.5 With peripheral circulatory complications
0.788 0.212 0.000
T43.3 Phenothiazine antipsychotics and neuroleptics
0.787 0.213 0.000
L40.1 Generalised pustular psoriasis
0.777 0.223 0.000
E05.9 Thyrotoxicosis, unspecified
0.000 0.229 0.771
M45.X2 Ankylosing spondylitis (Cervical region)
0.000 0.231 0.769
E65-E68 Obesity and other hyperalimentation
0.766 0.234 0.000
T44 Poisoning by drugs primarily affecting the autonomic nervous system
0.760 0.240 0.000
L40.8 Other psoriasis
0.745 0.255 0.000
T38 Poisoning by hormones and their synthetic substitutes and antagonists, not elsewhere classified
0.735 0.265 0.000
Chapter V Mental and behavioural disorders
0.727 0.273 0.000
T36 Poisoning by systemic antibiotics
0.724 0.276 0.000
E40-E46 Malnutrition
0.723 0.277 0.000
F30-F39 Mood [affective] disorders
0.722 0.278 0.000
E20-E35 Disorders of other endocrine glands
0.719 0.281 0.000
E70-E90 Metabolic disorders
0.719 0.281 0.000
E10.7 With multiple complications
0.717 0.283 0.000
L40.4 Guttate psoriasis
0.717 0.283 0.000
L40.3 Pustulosis palmaris et plantaris
0.717 0.283 0.000
L40.2 Acrodermatitis continua
0.717 0.283 0.000
E12 Malnutrition-related diabetes mellitus
0.717 0.283 0.000
E11.7 With multiple complications
0.716 0.284 0.000
F40-F48 Neurotic, stress-related and somatoform disorders
0.714 0.286 0.000
E11.6 With other specified complications
0.712 0.288 0.000
T50 Poisoning by diuretics and other and unspecified drugs, medicaments and biological substances
0.712 0.288 0.000
E14.8 With unspecified complications
0.710 0.290 0.000
E65 Localised adiposity
0.707 0.293 0.000
E10.6 With other specified complications
0.707 0.293 0.000
F41 Other anxiety disorders
0.705 0.295 0.000
E05.0 Thyrotoxicosis with diffuse goitre
0.001 0.298 0.700
E10.2 With renal complications
0.696 0.304 0.000
F32 Depressive episode
0.696 0.304 0.000
E16.0 Drug-induced hypoglycaemia without coma
0.694 0.306 0.000
F32.9 Depressive episode, unspecified
0.688 0.312 0.000
E14.1 With ketoacidosis
0.687 0.313 0.000
F30 Manic episode
0.685 0.315 0.000
F60-F69 Disorders of adult personality and behaviour
0.677 0.323 0.000
L40-L45 Papulosquamous disorders
0.675 0.325 0.000
T43.4 Butyrophenone and thioxanthene neuroleptics
0.671 0.329 0.000
F41.2 Mixed anxiety and depressive disorder
0.670 0.330 0.000
T48 Poisoning by agents primarily acting on smooth and skeletal muscles and the respiratory system
0.668 0.332 0.000
T44.9 Other and unspecified drugs primarily affecting the nervous system
0.664 0.336 0.000
T46 Poisoning by agents primarily affecting the cardiovascular system
0.658 0.342 0.000
E03.8 Other specified hypothyroidism
0.007 0.342 0.651
E78 Disorders of lipoprotein metabolism and other lipidaemias
0.653 0.347 0.000
T42 Poisoning by antiepileptic, sedative-hypnotic and anti-Parkinsonism drugs
0.651 0.349 0.000
E78.0 Pure hypercholesterolaemia
0.648 0.352 0.000
F30.0 Hypomania
0.648 0.352 0.000
T37 Poisoning by other systemic anti-infectives and antiparasitics
0.648 0.352 0.000
E14.4 With neurological complications
0.647 0.353 0.000
F60 Specific personality disorders
0.645 0.355 0.000
F41.9 Anxiety disorder, unspecified
0.638 0.362 0.000
F44 Dissociative [conversion] disorders
0.633 0.367 0.000
E14.7 With multiple complications
0.632 0.368 0.000
E14.5 With peripheral circulatory complications
0.632 0.368 0.000
E14.2 Withrenal complications
0.632 0.368 0.000
E14.0 With coma
0.632 0.368 0.000
M45.X8 Ankylosing spondylitis (Sacral and sacrococcygeal region)
0.000 0.369 0.631
M45.X7 Ankylosing spondylitis (Lumbosacral region)
0.000 0.369 0.631
M45.X6 Ankylosing spondylitis (Lumbar region)
0.000 0.369 0.631
M45.X5 Ankylosing spondylitis (Thoracolumbar region)
0.000 0.369 0.631
M45.X4 Ankylosing spondylitis (Thoracic region)
0.000 0.369 0.631
M45.X3 Ankylosing spondylitis (Cervicothoracic region)
0.000 0.369 0.631
M45.X1 Ankylosing spondylitis (Occipito-atlanto-axial region)
0.000 0.369 0.631
E89 Postprocedural endocrine and metabolic disorders, not elsewhere classified
0.630 0.370 0.000
E15 Nondiabetic hypoglycaemic coma
0.628 0.371 0.000
T39.9 Nonopioid analgesic, antipyretic and antirheumatic, unspecified
0.628 0.372 0.000
E14.6 With other specified complications
0.626 0.374 0.000
E13 Other specified diabetes mellitus
0.624 0.375 0.000
E21 Hyperparathyroidism and other disorders of parathyroid gland
0.623 0.377 0.000
E03.5 Myxoedema coma
0.009 0.378 0.613
E03.4 Atrophy of thyroid (acquired)
0.009 0.378 0.613
E03.3 Postinfectious hypothyroidism
0.009 0.378 0.613
E03.1 Congenital hypothyroidism without goitre
0.009 0.378 0.613
T36.0 Penicillins
0.620 0.380 0.000
T38.3 Insulin and oral hypoglycaemic [antidiabetic] drugs
0.619 0.381 0.000
F50-F59 Behavioural syndromes associated with physiological disturbances and physical factors
0.617 0.383 0.000
F45 Somatoform disorders
0.616 0.384 0.000
T47 Poisoning by agents primarily affecting gastro-intestinal system
0.616 0.384 0.000
T44.7 Beta-Adrenoreceeptor antagonists, not elsewhere classified
0.612 0.388 0.000
E86 Volume depletion
0.608 0.392 0.000
E26 Hyperaldosteronism
0.605 0.395 0.000
E16.9 Disorder of pancreatic internal secretion, unspecified
0.604 0.396 0.000
E16.8 Other specified disorders of pancreatic internal secretion
0.604 0.396 0.000
E16.4 Abnormal secretion of gastrin
0.604 0.396 0.000
E16.3 Increased secretion of glucagon
0.604 0.396 0.000
E89.3 Postprocedural hypopituitarism
0.604 0.396 0.000
T43.5 Other and unspecified antipsychotics and neuroleptics
0.600 0.400 0.000
T50.9 Other and unspecified drugs, medicaments and biological substances
0.599 0.401 0.000
T49 Poisoning by topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinolarygological and dental drugs
0.596 0.403 0.000
T41 Poisoning by anaesthetics and therapeutic gases
0.596 0.403 0.000
T43.9 Psychotropic drug, unspecified
0.595 0.405 0.000
T43.8 Other psychotropic drugs, not elsewhere classified
0.595 0.405 0.000
T43.1 Monoamine-oxidase-inhibitor antidepressants
0.595 0.405 0.000
F60.9 Personality disorder, unspecified
0.594 0.406 0.000
T44.3 Other parasympatholytics [anticholinergics and antimuscarines] and spasmolytics, not elsewhere classified
0.592 0.408 0.000
T38.1 Thyroid hormones and substitutes
0.591 0.409 0.000
E01 Iodine-deficiency-related thyroid disorders and allied conditions
0.018 0.415 0.568
E00 Congenital iodine-deficiency syndrome
0.018 0.415 0.568
E02 Subclinical iodine-deficiency hypothyroidism
0.018 0.415 0.568
F32.0 Mild depressive episode
0.583 0.417 0.000
F60.3 Emotionally unstable personality disorder
0.582 0.418 0.000
T39.4 Antirheumatics, not elsewhere classified
0.582 0.418 0.000
T39.2 Pyrazolone derivatives
0.582 0.418 0.000
E46 Unspecified protein-energy malnutrition
0.579 0.421 0.000
E34 Other endocrine disorders
0.578 0.422 0.000
E11.5 With peripheral circulatory complications
0.577 0.422 0.000
F80-F89 Disorders of psychological development
0.573 0.427 0.000
F41.3 Other mixed anxiety disorders
0.572 0.428 0.000
T36.4 Tetracyclines
0.571 0.429 0.000
F10-F19 Mental and behavioural disorders due to psychoactive substance use
0.569 0.431 0.000
E11.8 With unspecified complications
0.569 0.431 0.000
T43.6 Psychostimulants with abuse potential
0.569 0.431 0.000
E21.3 Hyperparathyroidism, unspecified
0.568 0.432 0.000
F33 Recurrent depressive disorder
0.567 0.433 0.000
E05.5 Thyroid crisis or storm
0.007 0.434 0.559
E05.4 Thyrotoxicosis factitia
0.007 0.434 0.559
E05.3 Thyrotoxicosis from ectopic thyroid tissue
0.007 0.434 0.559
E05.1 Thyrotoxicosis with toxic single thyroid nodule
0.007 0.434 0.559
# Top node
0.566 0.434 0.000
F32.2 Severe depressive episode without psychotic symptoms
0.565 0.435 0.000
Chapter XII Diseases of the skin and subcutaneous tissue
0.563 0.437 0.000
F00-F09 Organic, including symptomatic, mental disorders
0.560 0.440 0.000
E06 Thyroiditis
0.014 0.441 0.545
T38.6 Antigonadotrophins. antioestrogens, antiandrogens, not elsewhere classified
0.554 0.446 0.000
F48 Other neurotic disorders
0.552 0.448 0.000
T48.6 Antiasthmatics, not elsewhere classified
0.550 0.450 0.000
T46.2 Other antidysrhythmic drugs, not elsewhere classified
0.550 0.450 0.000
E67 Other hyperalimentation
0.549 0.450 0.000
E68 Sequelae of hyperalimentation
0.549 0.450 0.000
T39.0 Salicylates
0.549 0.451 0.000
E03.2 Hypothyroidism due to medicaments and other exogenous substances
0.009 0.451 0.540
E88 Other metabolic disorders
0.549 0.451 0.000
F17 Mental and behavioural disorders due to use of tobacco
0.548 0.452 0.000
H65-H75 Diseases of middle ear and mastoid
0.548 0.452 0.000
T50.4 Drugs affecting uric acid metabolism
0.547 0.453 0.000
F50 Eating disorders
0.547 0.453 0.000
E74 Other disorders of carbohydrate metabolism
0.546 0.454 0.000
Chapter VIII Diseases of the ear and mastoid process
0.546 0.454 0.000
T44.8 Centrally acting and afrenergic-neuron-blocking agents, not elsewhere classified
0.545 0.455 0.000
T44.6 Alpha-Adrenoreceeptor antagonists, not elsewhere classified
0.545 0.455 0.000
T44.5 Predominantly Beta-adrenoreceptor agonists, not elsewhere classified
0.545 0.455 0.000
T44.4 Predominantly Alpha-adrenoreceptor agonists, not elsewhere classified
0.545 0.455 0.000
T44.2 Ganglionic blocking drugs, not elsewhere classified
0.545 0.455 0.000
T44.1 Other parasympathomimetics [cholinergics]
0.545 0.455 0.000
T44.0 Anticholinesterase agents
0.545 0.455 0.000
Chapter XX External causes of morbidity and mortality
0.543 0.457 0.000
E85 Amyloidosis
0.543 0.457 0.000
F17.1 Harmful use
0.543 0.457 0.000
F30.9 Manic episode, unspecified
0.539 0.461 0.000
H71 Cholesteatoma of middle ear
0.539 0.461 0.000
E89.1 Postprocedural hypoinsulinaemia
0.533 0.467 0.000
E20 Hypoparathyroidism
0.533 0.467 0.000
H65 Nonsuppurative otitis media
0.533 0.467 0.000
F39 Unspecified mood [affective] disorder
0.533 0.467 0.000
H65.3 Chronic mucoid otitis media
0.533 0.467 0.000
F45.9 Somatoform disorder, unspecified
0.532 0.468 0.000
T46.6 Antihyperlipidaemic and antiarteriosclerotic drugs
0.530 0.470 0.000
F41.1 Generalised anxiety disorder
0.529 0.471 0.000
T38.9 Other and unspecified hormone antagonists
0.527 0.473 0.000
T38.8 Other and unspecified hormones and their synthetic substitutes
0.527 0.473 0.000
T38.7 Androgens and anabolic congeners
0.527 0.473 0.000
T38.5 Other oestrogens and progestogens
0.527 0.473 0.000
T38.4 Oral contraceptives
0.527 0.473 0.000
T38.2 Antithyroid drugs
0.527 0.473 0.000
T38.0 Glucocorticoids and synthetic analogues
0.527 0.473 0.000
F44.9 Dissociative [conversion] disorder, unspecified
0.526 0.474 0.000
T50.2 Carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics
0.525 0.475 0.000
E07 Other disorders of thyroid
0.012 0.477 0.511
E26.0 Primary hyperaldosteronism
0.523 0.477 0.000
F90-F98 Behavioural and emotional disorders with onset usually occurring in childhood and adolescence
0.521 0.478 0.000
Y40-Y59 Drugs, medicaments and biological substances causing adverse effects in therapeutic use
0.520 0.480 0.000
E05.8 Other thyrotoxicosis
0.007 0.480 0.512
T36.9 Systemic antibiotic, unspecified
0.519 0.481 0.000
T36.8 Other systemic antibiotics
0.519 0.481 0.000
T36.7 Antifungal antibiotics, systemically used
0.519 0.481 0.000
T36.6 Rifamycins
0.519 0.481 0.000
T36.5 Aminoglycosides
0.519 0.481 0.000
T36.3 Macrolides
0.519 0.481 0.000
T36.2 Chloramphenicol group
0.519 0.481 0.000
T36.1 Cefalosporins and other Beta-lactam antibiotics
0.519 0.481 0.000
E44 Protein-energy malnutrition of moderate and mild degree
0.519 0.481 0.000
E45 Retarded development following protein-energy malnutrition
0.519 0.481 0.000
E43 Unspecified severe protein-energy malnutrition
0.519 0.481 0.000
E42 Marasmic kwashiorkor
0.519 0.481 0.000
E41 Nutritional marasmus
0.519 0.481 0.000
E40 Kwashiorkor
0.519 0.481 0.000
E78.2 Mixed hyperlipidaemia
0.518 0.482 0.000
F38 Other mood [affective] disorders
0.517 0.482 0.000
T37.8 Other specified systemic anti-infectives and antiparasitics
0.516 0.484 0.000
E35 Disorders of endocrine glands in diseases classified elsewhere
0.515 0.484 0.000
E32 Diseases of thymus
0.515 0.484 0.000
E31 Polyglandular dysfunction
0.515 0.484 0.000
E30 Disorders of puberty, not elsewhere classified
0.515 0.484 0.000
E25 Adrenogenital disorders
0.515 0.484 0.000
F80 Specific developmental disorders of speech and language
0.515 0.485 0.000
E84 Cystic fibrosis
0.515 0.485 0.000
E77 Disorders of glycoprotein metabolism
0.515 0.485 0.000
E76 Disorders of glycosaminoglycan metabolism
0.515 0.485 0.000
E75 Disorders of sphingolipid metabolism and other lipid storage disorders
0.515 0.485 0.000
E72 Other disorders of amino-acid metabolism
0.515 0.485 0.000
E71 Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism
0.515 0.485 0.000
E70 Disorders of aromatic amino-acid metabolism
0.515 0.485 0.000
E90 Nutritional and metabolic disorders in diseases classified elsewhere
0.515 0.485 0.000
E12.9 Without complications
0.514 0.486 0.000
E12.8 With unspecified complications
0.514 0.486 0.000
E12.7 With multiple complications
0.514 0.486 0.000
E12.6 With other specified complications
0.514 0.486 0.000
E12.5 With peripheral circulatory complications
0.514 0.486 0.000
E12.4 With neurological complications
0.514 0.486 0.000
E12.3 With ophthalmic complications
0.514 0.486 0.000
E12.2 With renal complications
0.514 0.486 0.000
E12.1 With ketoacidosis
0.514 0.486 0.000
E12.0 With coma
0.514 0.486 0.000
F69 Unspecified disorder of adult personality and behaviour
0.513 0.487 0.000
E03.0 Congenital hypothyroidism with diffuse goitre
0.011 0.488 0.501
F44.5 Dissociative convulsions
0.511 0.489 0.000
T50.8 Diagnostic agents
0.511 0.489 0.000
T50.7 Analeptics and opioid receptor antagonists
0.511 0.489 0.000
T50.6 Antidotes and chelating agents, not elsewhere classified
0.511 0.489 0.000
T50.5 Appetite depressants
0.511 0.489 0.000
T50.3 Electrolytic, caloric and water-balance agents
0.511 0.489 0.000
T50.1 Loop [high-ceiling] diuretics
0.511 0.489 0.000
T50.0 Mineralocorticoids and their antagonists
0.511 0.489 0.000
K90 Intestinal malabsorption
0.000 0.491 0.509
F70-F79 Mental retardation
0.509 0.491 0.000
E79 Disorders of purine and pyrimidine metabolism
0.509 0.491 0.000
F41.8 Other specified anxiety disorders
0.505 0.495 0.000
E34.0 Carcinoid syndrome
0.505 0.495 0.000
T42.4 Benzodiazepines
0.504 0.496 0.000
F30.2 Mania with psychotic symptoms
0.501 0.499 0.000
F41.0 Panic disorder [episodic paroxysmal anxiety]
0.495 0.505 0.000
E21.5 Disorder of parathyroid gland, unspecified
0.493 0.507 0.000
E16.1 Other hypoglycaemia
0.492 0.508 0.000
F30.8 Other manic episodes
0.491 0.509 0.000
F30.1 Mania without psychotic symptoms
0.491 0.509 0.000
F34 Persistent mood [affective] disorders
0.491 0.509 0.000
T42.7 Antiepileptic and sedative-hypnotic drugs, unspecified
0.491 0.509 0.000
E22 Hyperfunction of pituitary gland
0.490 0.510 0.000
F44.4 Dissociative motor disorders
0.488 0.512 0.000
E78.6 Lipoprotein deficiency
0.487 0.513 0.000
F45.8 Other somatoform disorders
0.486 0.514 0.000
F68 Other disorders of adult personality and behaviour
0.486 0.514 0.000
F66 Psychological and behavioural disorders associated with sexual development and orientation
0.486 0.514 0.000
F65 Disorders of sexual preference
0.486 0.514 0.000
F63 Habit and impulse disorders
0.486 0.514 0.000
F62 Enduring personality changes, not attributable to brain damage and disease
0.486 0.514 0.000
F61 Mixed and other personality disorders
0.486 0.514 0.000
E23 Hypofunction and other disorders of pituitary gland
0.485 0.515 0.000
T43.0 Tricyclic and tetracyclic antidepressants
0.484 0.516 0.000
F06 Other mental disorders due to brain damage and dysfunction and to physical disease
0.484 0.516 0.000
L44 Other papulosquamous disorders
0.484 0.516 0.000
L41 Parapsoriasis
0.484 0.516 0.000
L45 Papulosquamous disorders in diseases classified elsewhere
0.484 0.516 0.000
V10-V19 Pedal cyclist injured in transport accident
0.484 0.516 0.000
F42 Obsessive-compulsive disorder
0.481 0.519 0.000
W75-W84 Other accidental threats to breathing
0.481 0.519 0.000
F99-F99 Unspecified mental disorder
0.480 0.520 0.000
T42.6 Other antiepileptic and sedative-hypnotic drugs
0.480 0.520 0.000
F32.8 Other depressive episodes
0.479 0.520 0.000
T48.7 Other and unspecified agents primarily acting on the respiratory system
0.479 0.521 0.000
T48.5 Anti-common-cold drugs
0.479 0.521 0.000
T48.4 Expectorants
0.479 0.521 0.000
T48.3 Antitussives
0.479 0.521 0.000
T48.2 Other and unspecified agents primarily acting on muscles
0.479 0.521 0.000
T48.1 Skeletal muscle relaxants [neuromuscular blocking agents]
0.479 0.521 0.000
T48.0 Oxytocic drugs
0.479 0.521 0.000
F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms
0.479 0.521 0.000
L00-L08 Infections of the skin and subcutaneous tissue
0.478 0.522 0.000
E24 Cushing's syndrome
0.476 0.524 0.000
Y52 Agents primarily affecting the cardiovascular system
0.474 0.526 0.000
F02 Dementia in other diseases classified elsewhere
0.473 0.527 0.000
T46.9 Other and unspecified agents primarily affecting the cardiovascular system
0.472 0.528 0.000
T46.8 Antivaricose drugs, including sclerosing agents
0.472 0.528 0.000
T46.7 Peripheral vasodilators
0.472 0.528 0.000
T46.3 Coronary vasodilators, not elsewhere classified
0.472 0.528 0.000
T46.0 Cardiac-stimulant glycosides and drugs of similar action
0.472 0.528 0.000
T39.8 Other nonopioid analgesics and antipyretics, not elsewhere classified
0.472 0.528 0.000
L03.3 Cellulitis of trunk
0.471 0.529 0.000
E21.2 Other hyperparathyroidism
0.470 0.529 0.000
E78.1 Pure hyperglyceridaemia
0.470 0.530 0.000
F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms
0.469 0.531 0.000
E78.3 Hyperchylomicronaemia
0.468 0.532 0.000
E89.6 Postprocedural adrenocortical(-medullary) hypofunction
0.468 0.532 0.000
F20-F29 Schizophrenia, schizotypal and delusional disorders
0.467 0.533 0.000
T42.8 Anti-Parkinsonism drugs and other central muscle-tone depressants
0.467 0.533 0.000
T42.5 Mixed antiepileptics, not elsewhere classified
0.467 0.533 0.000
T42.3 Barbiturates
0.467 0.533 0.000
T42.2 Succinimides and oxazolidinediones
0.467 0.533 0.000
T37.9 Systemic anti-infective and antiparasitic, unspecified
0.464 0.535 0.000
T37.5 Antiviral drugs
0.464 0.535 0.000
T37.4 Anthelminthics
0.464 0.535 0.000
T37.3 Other antiprotozoal drugs
0.464 0.535 0.000
T37.2 Antimalarials and drugs acting on other blood protozoa
0.464 0.535 0.000
T37.1 Antimycobacterial drugs
0.464 0.535 0.000
T37.0 Sulphonamides
0.464 0.535 0.000
T46.4 Angiotensin-converting-enzyme inhibitors
0.463 0.537 0.000
F60.8 Other specific personality disorders
0.462 0.538 0.000
F60.4 Histrionic personality disorder
0.462 0.538 0.000
F60.2 Dissocial personality disorder
0.462 0.538 0.000
F60.1 Schizoid personality disorder
0.462 0.538 0.000
F60.0 Paranoid personality disorder
0.462 0.538 0.000
T47.1 Other antacids and anti-gastric-secretion drugs
0.461 0.539 0.000
Y59 Other and unspecified vaccines and biological substances
0.461 0.539 0.000
T42.1 Iminostilbenes
0.460 0.540 0.000
T46.5 Other antihypertensive drugs, not elsewhere classified
0.459 0.541 0.000
T42.0 Hydantoin derivatives
0.457 0.543 0.000
Y43 Primarily systemic agents
0.457 0.543 0.000
F50.2 Bulimia nervosa
0.456 0.544 0.000
L03 Cellulitis
0.455 0.545 0.000
F60.5 Anankastic personality disorder
0.454 0.546 0.000
F44.8 Other dissociative [conversion] disorders
0.454 0.546 0.000
F44.7 Mixed dissociative [conversion] disorders
0.454 0.546 0.000
F44.6 Dissociative anaesthesia and sensory loss
0.454 0.546 0.000
F44.3 Trance and possession disorders
0.454 0.546 0.000
F44.2 Dissociative stupor
0.454 0.546 0.000
F44.1 Dissociative fugue
0.454 0.546 0.000
F44.0 Dissociative amnesia
0.454 0.546 0.000
E89.9 Postprocedural endocrine and metabolic disorder, unspecified
0.451 0.548 0.000
E89.8 Other postprocedural endocrine and metabolic disorders
0.451 0.548 0.000
E89.5 Postprocedural testicular hypofunction
0.451 0.548 0.000
E89.4 Postprocedural ovarian failure
0.451 0.548 0.000
F31 Bipolar affective disorder
0.449 0.551 0.000
E13.8 With unspecified complications
0.448 0.552 0.000
E13.7 With multiple complications
0.448 0.552 0.000
E13.6 With other specified complications
0.448 0.552 0.000
E13.5 With peripheral circulatory complications
0.448 0.552 0.000
E13.4 With neurological complications
0.448 0.552 0.000
E13.3 With ophthalmic complications
0.448 0.552 0.000
E13.2 With renal complications
0.448 0.552 0.000
E13.1 With ketoacidosis
0.448 0.552 0.000
E13.0 With coma
0.448 0.552 0.000
F80.1 Expressive language disorder
0.448 0.552 0.000
X60-X84 Intentional self-harm
0.447 0.553 0.000
F17.0 Acute intoxication
0.447 0.553 0.000
Y70-Y82 Medical devices associated with adverse incidents in diagnostic and therapeutic use
0.447 0.553 0.000
E21.4 Other specified disorders of parathyroid gland
0.447 0.553 0.000
V70-V79 Bus occupant injured in transport accident
0.446 0.553 0.000
K90.9 Intestinal malabsorption, unspecified
0.000 0.556 0.444
E29 Testicular dysfunction
0.444 0.556 0.000
Y00-Y09 Assault
0.444 0.556 0.000
F60.6 Anxious [avoidant] personality disorder
0.442 0.557 0.000
F53 Mental and behavioural disorders associated with the puerperium, not elsewhere classified
0.442 0.558 0.000
F51 Nonorganic sleep disorders
0.442 0.558 0.000
F59 Unspecified behavioural syndromes associated with physiological disturbances and physical factors
0.442 0.558 0.000
F55 Abuse of non-dependence-producing substances
0.442 0.558 0.000
F54 Psychological and behavioural factors associated with disorders or diseases classified elsewhere
0.442 0.558 0.000
F45.4 Persistent somatoform pain disorder
0.442 0.558 0.000
F45.2 Hypochondriacal disorder
0.442 0.558 0.000
F45.1 Undifferentiated somatoform disorder
0.442 0.558 0.000
F45.0 Somatisation disorder
0.442 0.558 0.000
T47.9 Agent primarily affecting the gastro-intestinal system, unspecified
0.441 0.558 0.000
T47.8 Other agents primarily affecting the gastro-intestinal system
0.441 0.558 0.000
T47.7 Emetics
0.441 0.558 0.000
T47.6 Antidiarrhoeal drugs
0.441 0.558 0.000
T47.5 Digestants
0.441 0.558 0.000
T47.4 Other laxatives
0.441 0.558 0.000
T47.3 Saline and osmotic laxatives
0.441 0.558 0.000
T47.2 Stimulant laxatives
0.441 0.558 0.000
T47.0 Histamine H(2)-receptor antagonists
0.441 0.558 0.000
F50.9 Eating disorder, unspecified
0.441 0.558 0.000
Y43.1 Antineoplastic antimetabolites
0.440 0.560 0.000
H72 Perforation of tympanic membrane
0.439 0.561 0.000
E27 Other disorders of adrenal gland
0.439 0.561 0.000
Y56 Topical agents primarily affecting skin and mucous membrane and ophthalmological, otorhinolaryngological and dental drugs
0.439 0.561 0.000
F64 Gender identity disorders
0.437 0.563 0.000
V95-V97 Air and space transport accidents
0.436 0.564 0.000
Y57 Other and unspecified drugs and medicaments
0.435 0.565 0.000
X30-X39 Exposure to forces of nature
0.434 0.566 0.000
X00-X09 Exposure to smoke, fire and flames
0.434 0.566 0.000
E26.9 Hyperaldosteronism, unspecified
0.433 0.566 0.000
E26.8 Other hyperaldosteronism
0.433 0.566 0.000
E26.1 Secondary hyperaldosteronism
0.433 0.566 0.000
F48.9 Neurotic disorder, unspecified
0.433 0.567 0.000
T45 Poisoning by primarily systemic and haematological agents, not elsewhere classified
0.432 0.567 0.000
V80-V89 Other land transport accidents
0.432 0.568 0.000
E88.1 Lipodystrophy, not elsewhere classified
0.431 0.568 0.000
L05 Pilonidal cyst
0.431 0.569 0.000
F13 Mental and behavioural disorders due to use of sedatives or hypnotics
0.430 0.570 0.000
W50-W64 Exposure to animate mechanical forces
0.429 0.571 0.000
F60.7 Dependent personality disorder
0.428 0.572 0.000
T41.5 Therapeutic gases
0.428 0.572 0.000
T41.4 Anaesthetic, unspecified
0.428 0.572 0.000
T41.3 Local anaesthetics
0.428 0.572 0.000
T41.2 Other and unspecified general anaesthetics
0.428 0.572 0.000
T41.1 Intravenous anaesthetics
0.428 0.572 0.000
T41.0 Inhaled anaesthetics
0.428 0.572 0.000
T49.9 Topical agent, unspecified
0.428 0.572 0.000
T49.8 Other topical agents
0.428 0.572 0.000
T49.7 Dental drugs, topically applied
0.428 0.572 0.000
T49.6 Otorhinolaryngological drugs and preparations
0.428 0.572 0.000
T49.5 Ophthalmological drugs and preparations
0.428 0.572 0.000
T49.4 Keratolytics, keratoplastics and other hair treatment drugs and preparations
0.428 0.572 0.000
T49.3 Emollients, demulcents and protectants
0.428 0.572 0.000
T49.2 Local astringents and local detergents
0.428 0.572 0.000
T49.1 Antipruritics
0.428 0.572 0.000
T49.0 Local antifungal, anti-infective and anti-inflammatory drugs, not elsewhere classified
0.428 0.572 0.000
V18 Pedal cyclist injured in noncollision transport accident
0.428 0.572 0.000
F80.2 Receptive language disorder
0.426 0.574 0.000
F45.3 Somatoform autonomic dysfunction
0.423 0.577 0.000
F07 Personality and behavioural disorders due to brain disease, damage and dysfunction
0.423 0.577 0.000
E74.3 Other disorders of intestinal carbohydrate absorption
0.423 0.577 0.000
F03 Unspecified dementia
0.423 0.577 0.000
E06.3 Autoimmune thyroiditis
0.005 0.577 0.417
E85.4 Organ-limited amyloidosis
0.422 0.578 0.000
F50.0 Anorexia nervosa
0.421 0.579 0.000
E73 Lactose intolerance
0.421 0.579 0.000
T39.3 Other nonsteroidal anti-inflammatory drugs [NSAID]
0.420 0.580 0.000
H90-H95 Other disorders of ear
0.420 0.580 0.000
E00.9 Congenital iodine-deficiency syndrome, unspecified
0.013 0.580 0.407
E00.2 Congenital iodine-deficiency syndrome, mixed type
0.013 0.580 0.407
E00.1 Congenital iodine-deficiency syndrome, myxoedematous type
0.013 0.580 0.407
E00.0 Congenital iodine-deficiency syndrome, neurological type
0.013 0.580 0.407
E01.8 Other iodine-deficiency-related thyroid disorders and allied conditions
0.013 0.580 0.407
E01.2 Iodine-deficiency-related (endemic) goitre, unspecified
0.013 0.580 0.407
E01.1 Iodine-deficiency-related multinodular (endemic) goitre
0.013 0.580 0.407
E01.0 Iodine-deficiency-related diffuse (endemic) goitre
0.013 0.580 0.407
F52 Sexual dysfunction, not caused by organic disorder or disease
0.420 0.580 0.000
V40-V49 Car occupant injured in transport accident
0.419 0.581 0.000
Chapter XXII Codes for special purposes
0.419 0.581 0.000
Y59.3 Immunoglobulin
0.419 0.581 0.000
H73 Other disorders of tympanic membrane
0.418 0.582 0.000
E23.7 Disorder of pituitary gland, unspecified
0.418 0.582 0.000
Y10-Y34 Event of undetermined intent
0.417 0.582 0.000
E80 Disorders of porphyrin and bilirubin metabolism
0.417 0.583 0.000
Chapter XIX Injury, poisoning and certain other consequences of external causes
0.417 0.583 0.000
Y46 Antiepileptics and anti-Parkinsonism drugs
0.416 0.584 0.000
L20-L30 Dermatitis and eczema
0.416 0.584 0.000
Y52.5 Other antihypertensive drugs, not elsewhere classified
0.415 0.585 0.000
H66 Suppurative and unspecified otitis media
0.415 0.585 0.000
E34.5 Androgen resistance syndrome
0.414 0.586 0.000
E34.4 Constitutional tall stature
0.414 0.586 0.000
E34.3 Short stature, not elsewhere classified
0.414 0.586 0.000
E34.2 Ectopic hormone secretion, not elsewhere classified
0.414 0.586 0.000
E34.1 Other hypersecretion of intestinal hormones
0.414 0.586 0.000
E28 Ovarian dysfunction
0.413 0.587 0.000
E78.8 Other disorders of lipoprotein metabolism
0.413 0.587 0.000
L43 Lichen planus
0.412 0.588 0.000
F06.7 Mild cognitive disorder
0.412 0.588 0.000
F15 Mental and behavioural disorders due to use of other stimulants, including caffeine
0.412 0.588 0.000
E50-E64 Other nutritional deficiencies
0.411 0.589 0.000
F89 Unspecified disorder of psychological development
0.411 0.589 0.000
F88 Other disorders of psychological development
0.411 0.589 0.000
F83 Mixed specific developmental disorders
0.411 0.589 0.000
F82 Specific developmental disorder of motor function
0.411 0.589 0.000
X40-X49 Accidental poisoning by and exposure to noxious substances
0.411 0.589 0.000
V90-V94 Water transport accidents
0.410 0.590 0.000
E34.8 Other specified endocrine disorders
0.409 0.591 0.000
Y41 Other systemic anti-infectives and antiparasitics
0.409 0.591 0.000
F18 Mental and behavioural disorders due to use of volatile solvents
0.408 0.592 0.000
F16 Mental and behavioural disorders due to use of hallucinogens
0.408 0.592 0.000
F14 Mental and behavioural disorders due to use of cocaine
0.408 0.592 0.000
E22.0 Acromegaly and pituitary gigantism
0.408 0.592 0.000
F33.8 Other recurrent depressive disorders
0.406 0.594 0.000
F33.4 Recurrent depressive disorder, currently in remission
0.406 0.594 0.000
Chapter XVI Certain conditions originating in the perinatal period
0.406 0.594 0.000
E88.2 Lipomatosis, not elsewhere classified
0.402 0.598 0.000
F09 Unspecified organic or symptomatic mental disorder
0.401 0.598 0.000
F04 Organic amnesic syndrome, not induced by alcohol and other psychoactive substances
0.401 0.598 0.000
E06.5 Other chronic thyroiditis
0.010 0.599 0.391
E06.4 Drug-induced thyroiditis
0.010 0.599 0.391
E06.2 Chronic thyroiditis with transient thyrotoxicosis
0.010 0.599 0.391
E06.1 Subacute thyroiditis
0.010 0.599 0.391
E06.0 Acute thyroiditis
0.010 0.599 0.391

This table lists the top 500 terms ordered by p(effect).

The full results table can be downloaded from this page.

 

The TreeWAS Database is the result of research conducted at the Oxford Big Data Institute at the University of Oxford.

This research has been conducted using the UK Biobank Resource (application number 10625). This work uses data provided by patients and collected by the NHS as part of their care and support.

This research has been conducted with the support of the Wellcome Trust (100956/Z/13/Z and 090532/Z/09/Z and 100308/Z/12/Z), the Danish National Research Foundation, Takeda, the Medical Research Council (MC_UU_12010/3), the Oak Foundation (OCAY-15-520), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the Wellcome Trust/Royal Society (204290/Z/16/Z) and the Li Ka Shing Foundation.

This website was created, designed, and edited by ORCID iD iconPatrick K. Albers

The contents of TreeWAS.org are available under the Creative Commons Attribution 4.0 International License (CC BY 4.0) with attribution (citation) required.

TreeWAS Database © 2019 - 2024 About Frequently Asked Questions Citation Contact Terms & Conditions This website does not use cookies to collect any personal information about you.